These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood. Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796 [TBL] [Abstract][Full Text] [Related]
14. Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. Pont-Sunyer C; Iranzo A; Gaig C; Fernández-Arcos A; Vilas D; Valldeoriola F; Compta Y; Fernández-Santiago R; Fernández M; Bayés A; Calopa M; Casquero P; de Fàbregues O; Jaumà S; Puente V; Salamero M; José Martí M; Santamaría J; Tolosa E PLoS One; 2015; 10(7):e0132368. PubMed ID: 26177462 [TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease. Thaler A; Shenhar-Tsarfaty S; Shaked Y; Gurevich T; Omer N; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Giladi N; Mirelman A Sci Rep; 2020 Jun; 10(1):9329. PubMed ID: 32518334 [TBL] [Abstract][Full Text] [Related]
16. Connectivity of corticostriatal circuits in nonmanifesting LRRK2 G2385R and R1628P carriers. Zhang D; Yao J; Ma J; Gao L; Sun J; Fang J; He H; Wu T CNS Neurosci Ther; 2022 Dec; 28(12):2024-2031. PubMed ID: 35934920 [TBL] [Abstract][Full Text] [Related]
17. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2 Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186 [TBL] [Abstract][Full Text] [Related]
18. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161 [TBL] [Abstract][Full Text] [Related]
19. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. van Nuenen BF; Helmich RC; Ferraye M; Thaler A; Hendler T; Orr-Urtreger A; Mirelman A; Bressman S; Marder KS; Giladi N; van de Warrenburg BP; Bloem BR; Toni I; Brain; 2012 Dec; 135(Pt 12):3687-98. PubMed ID: 23250886 [TBL] [Abstract][Full Text] [Related]
20. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls. Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]